← Back to Search

Hormone Therapy

Leptin + Pramlintide for Obesity

N/A
Waitlist Available
Led By Jonathan Q. Purnell, M.D.
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 year to 45 years of age
MI 18 to 25 kg/m2 or ≥ 30 kg/m2 at maximal lifetime weight
Must not have
Renal or hepatic impairment
Those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over 90 minutes
Awards & highlights
Approved for 5 Other Conditions

Summary

This trial is testing how well leptin and amylin work in obese people who have not been able to lose weight with other diets.

Who is the study for?
This trial is for adults aged 18-45 who are at their maximum lifetime weight and have maintained a stable weight for the last three months. They must have a BMI of either 18-25 or over 30. People with allergies to the study drugs, metal in their body, major illnesses, or those on certain medications cannot participate.
What is being tested?
The study is examining how leptin and amylin hormones affect brain regions involved in body weight control. Participants will receive infusions of metreleptin, pramlintide (amylin), both combined, or a placebo (normal saline) to assess this response using functional MRI.
What are the potential side effects?
Potential side effects from metreleptin and pramlintide may include allergic reactions due to sensitivity to E. coli-derived proteins used in these hormones' production process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 45 years old.
Select...
My BMI is either between 18-25 or was 30 or more at my heaviest.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have kidney or liver problems.
Select...
I have a major illness or need prescription medicine for conditions like cancer, heart disease, high blood pressure, or diabetes.
Select...
I do not have metal implants or objects in my body that could interfere with strong magnetic fields.
Select...
I am not allergic to metreleptin or pramlintide.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over 90 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and over 90 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To measure the fMRI response in the hypothalamus and brainstem, and whole brain, to intravenous leptin, pramlintide, combination leptin and pramlintide, and saline control.
Secondary study objectives
Timed blood samples during infusion will establish the time course for peak levels of infused hormones as well as detectable changes in insulin and glucose levels.

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: 4 Leptin plus PramlintideActive Control1 Intervention
leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
Group II: 2 MetreleptinActive Control1 Intervention
IV Leptin bolus
Group III: 3 PramlintideActive Control1 Intervention
IV Pramlintide bolus at Timpoint +0 and +30 minutes
Group IV: 1- Normal SalinePlacebo Group1 Intervention
4.7 mls normal saline IV bolus

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
1,002 Previous Clinical Trials
7,412,320 Total Patients Enrolled
29 Trials studying Obesity
9,336 Patients Enrolled for Obesity
Jonathan Q. Purnell, M.D.Principal InvestigatorOHSU - Center for the Study of Weight Regulation
4 Previous Clinical Trials
253 Total Patients Enrolled
4 Trials studying Obesity
253 Patients Enrolled for Obesity

Media Library

2 Metreleptin (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00691158 — N/A
Obesity Research Study Groups: 1- Normal Saline, 4 Leptin plus Pramlintide, 2 Metreleptin, 3 Pramlintide
Obesity Clinical Trial 2023: 2 Metreleptin Highlights & Side Effects. Trial Name: NCT00691158 — N/A
2 Metreleptin (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00691158 — N/A
~1 spots leftby Nov 2025